Gemina Laboratories Ltd. (GLABF)

Market Cap	54.27M
Revenue (ttm)	n/a
Net Income (ttm)	-2.45M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,100
Average Volume	17,056
Open	0.7300
Previous Close	0.7300
Day's Range	0.5305 - 0.7300
52-Week Range	0.2350 - 0.9194
Beta	0.59
RSI	37.52
Earnings Date	May 30, 2025

About Gemina Laboratories

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLABF

Financial Performance

Financial numbers in CAD